Holmes Biopharma, Inc.: January Highest Month of Sales to Date: Financial News

Holmes Biopharma, Inc.: January Highest Month of Sales to Date
Tuesday February 5, 9:00 am ET

SCOTTSDALE, ARIZONA--(MARKET WIRE)--Feb 5, 2008 -- Holmes Biopharma, Inc. (OTC BB:HLMB.OB - News) announces January sales for its Phase I operation in Omaha, Nebraska have reached 3 Million in awarded contracts. Furthermore, the Company expects to be operating the Omaha facility at full capacity through to June 2008 and anticipates this trend to continue.

"Traditionally, January is one of the slowest months of the year in sales activity and with surpassing our previous sales records we are succeeding in realizing our growth expectations," stated John Metcalfe, President and CEO, Holmes Biopharma, Inc.

About Holmes:

Holmes Biopharma, Inc. and it's wholly owned subsidiary, Qualia Clinical Service, Inc. is a contract research organization focused on providing integrated and cost effective clinical development services. Currently, clinics operate in Omaha, Nebraska USA, Toronto, Canada and Kiev, Ukraine, eastern Europe. For more information about the company please visit our website at www.holmesbiopharma.com.

On behalf of the Board of Directors

John F. Metcalfe, President and CEO

Certain statements in this press release constitute "forward looking statements" within the meaning of the United States Securities Legislation. The Company's actual results could differ from those in the forward-looking statements. Do not construe this information as investment advice. This is not a solicitation to buy or sell securities. This does not purport to be a complete analysis of the Company. Investing in securities is speculative and carries a high degree of risk. Past performance does not guarantee future results. Readers should consult their own independent advisers with any investment, including any contemplated investment. All information contained in this press release should be independently investigated. This press release contains forward-looking statements. These remarks involve risks and uncertainties. Risks are not limited to quarterly fluctuations in results or the companies' management of growth and competition. Other risks are detailed in the Company's SEC filings. Actual results may differ materially from such information set forth herein.